CCL2 and neoplasm: Inhibition of CCL2 has been shown to limit early metastatic processes in breast cancer; however, after cessation of therapy, increased metastatic spread is observed due to enhanced recruitment of monocytes to micrometastatic lesions in breast (86, 87) and lung (88, 89) metastasis mouse tumor models.